Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Drug Terashima: Sales Up to \37,883 Mil.
April 29, 2002
- 8 NCEs Including Infliximab Included in NHI Price List
April 29, 2002
- Showa Denko Develops Anesthetic Waste Gas Disposal System
April 29, 2002
- REGULATORY NEWS IN BRIEF
April 22, 2002
- Shimadzu Developing Next-generation DNA Sequencers
April 22, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 22, 2002
- MEDICAL DEVICE NEWS IN BRIEF
April 22, 2002
- Paxil's Sales Top \12 Bil. in 2001
April 22, 2002
- Meiji Seika to Promote Depromel to Non-specialists
April 22, 2002
- Hitachi Medical: Digital Ultrasound Diagnostic System
April 22, 2002
- Fujisawa Launches Protopic in Germany
April 22, 2002
- Olympus: VISERA Video System for Endoscopy
April 22, 2002
- AnGes MG Newly Agrees Agreement with Daiichi on HGF Gene Therapy
April 22, 2002
- Genzyme Promotes 4-Marker Maternal Serum Screening Test
April 22, 2002
- Nippon Roche, Chugai to Copromote Kytril
April 22, 2002
- Takeda: HICEE WHITE 2
April 22, 2002
- BUSINESS NEWS IN BRIEF
April 22, 2002
- Hac Kimisawa: Sales Up 6.7% to \144 Bil.
April 22, 2002
- WLJ: FY2001 Sales Up 8.8% to \46.2 Bil.
April 22, 2002
- Kirindo: Consolidated Sales Jump to \33 Bil.
April 22, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…